Mydecine Innovations Group Inc.
MYCOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $10 | $129 | $0 |
| Gross Profit | $0 | -$10 | -$129 | $7 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $0 | $1,084 | $3,589 | $3,960 |
| G&A Expenses | $1,395 | $7,153 | $9,983 | $14,745 |
| SG&A Expenses | $2,485 | $8,299 | $9,983 | $14,745 |
| Sales & Mktg Exp. | $1,090 | $1,146 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $2,137 | $3,402 |
| Operating Expenses | $2,485 | $9,383 | $15,709 | $22,107 |
| Operating Income | -$2,485 | -$9,392 | -$15,709 | -$22,099 |
| % Margin | – | – | – | -294,931% |
| Other Income/Exp. Net | -$667 | -$11,555 | -$36 | -$1,484 |
| Pre-Tax Income | -$3,152 | -$20,947 | -$15,745 | -$23,583 |
| Tax Expense | $0 | $0 | -$5,393 | $0 |
| Net Income | -$3,152 | -$20,947 | -$11,849 | -$28,897 |
| % Margin | – | – | – | -385,658.6% |
| EPS | -0.053 | -0.68 | -1.37 | -6.17 |
| % Growth | 92.2% | 50.4% | 77.8% | – |
| EPS Diluted | -0.053 | -0.68 | -1.37 | -6.17 |
| Weighted Avg Shares Out | 59,627 | 30,696 | 8,647 | 4,682 |
| Weighted Avg Shares Out Dil | 59,626 | 30,697 | 8,647 | 4,682 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $1,449 | $1,303 | $912 | $205 |
| Depreciation & Amortization | $10 | $10 | $129 | $235 |
| EBITDA | -$2,475 | -$9,383 | -$15,709 | -$23,142 |
| % Margin | – | – | – | -308,854.5% |